Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

133.08AUD
--
Change (% chg)

-- (--)
Prev Close
$133.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
939,299
52-wk High
$145.00
52-wk Low
$91.62

Latest Key Developments (Source: Significant Developments)

Seqirus receives FDA approval of afluria quadrivalent for people 5 years of age and older
Thursday, 14 Sep 2017 11:00am EDT 

Sept 14 (Reuters) - Csl Ltd :Seqirus receives FDA approval of afluria quadrivalent (influenza vaccine) for people five years of age and older in the U.S..Says ‍both afluria quadrivalent (influenza vaccine) and afluria (influenza vaccine), are available in U.S. for 2017-2018 influenza season​.  Full Article

CSL says no share buyback is foreshadowed in FY18
Tuesday, 15 Aug 2017 08:31pm EDT 

Aug 16 (Reuters) - CSL Ltd :Co’s FY18 NPAT "expected to be in the range of about $1,480 million to $1,550 million at constant currency".In first half FY18, CSL intends to approach us private placement market to raise approximately US$600 million for general corporate purposes."No share buyback is foreshadowed in FY18"."Expect solid ongoing demand for CSL Behring Biotherapies and strong market acceptance of our newly approved specialty product Haegarda".“Seqirus is expected to continue its path toward profitability”.  Full Article

CSL posts FY total revenue and other income of US$6,922.8 million
Tuesday, 15 Aug 2017 08:30pm EDT 

Aug 16 (Reuters) - CSL Ltd :FY total revenue and other income US$6,922.8 million versus versus US$6,129.2 million.Final dividend of US$0.72 per security unfranked.FY net profit after tax for the year attributable to members of the parent entity up 7.6 percent to US$1.34 billion.  Full Article

Humanwell Healthcare Group sells 80 pct stake in unit to CSL BEHRING ASIA PACIFIC for $351.8 mln
Friday, 4 Aug 2017 01:40am EDT 

Aug 4(Reuters) - Humanwell Healthcare Group Co Ltd <600079.SS>:Says it sold 80 percent stake in a wholly owned biological product unit to CSL BEHRING ASIA PACIFIC LTD for $351.8 million.  Full Article

CSL closes JV transaction with Humanwell Healthcare Group
Wednesday, 2 Aug 2017 06:43pm EDT 

Aug 3 (Reuters) - Csl Ltd :Closed a joint venture transaction with Humanwell Healthcare Group Co Ltd.Deal to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co Ltd.  Full Article

CSL Behring receives orphan-drug exclusivity for Haegarda
Friday, 21 Jul 2017 09:55am EDT 

July 21 (Reuters) - CSL Behring : :CSL Behring receives orphan-drug exclusivity for Haegarda® (C1 esterase inhibitor subcutaneous [human]).‍CSL Behring - U.S. FDA has granted company seven years of orphan-drug exclusivity for Haegarda​.  Full Article

FDA approves first subcutaneous C1 Esterase Inhibitor
Thursday, 22 Jun 2017 05:03pm EDT 

June 22 (Reuters) - U.S. Food and Drug Administration: :FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease.Granted approval of Haegarda to CSL Behring LLC.Haegarda is a C1 Esterase Inhibitor for subcutaneous administration to prevent Hereditary Angioedema attacks in adolescent & adult patients.Granted approval of Haegarda to CSL Behring LLC.  Full Article

Humanwell Healthcare to sell 80 pct stake in Wuhan unit to CSL Behring for about $351.8 mln
Monday, 12 Jun 2017 04:36am EDT 

June 12 (Reuters) - Humanwell Healthcare Group Co Ltd <600079.SS>:Says it signs agreement to sell 80 percent stake in its unit Wuhan Zhongyuan Ruide Biological Products Co to CSL Behring asia pacific ltd for about $351.8 million.  Full Article

CSL says Shire Viropharma has filed a complaint in US District Court for district of Delaware
Tuesday, 11 Apr 2017 09:08pm EDT 

Csl Ltd - : Has become aware that Shire Viropharma has filed a complaint in us district court for district of delaware . CSL remains highly confident that csl830 does not infringe any valid claim of shire viropharma patent and will vigorously defend against claims .Complaint alleging infringement of a newly granted us patent in connection with a method of treating hereditary angioedema.  Full Article

CSL says Shire Viropharma has filed a complaint in US District Court for district of Delaware
Tuesday, 11 Apr 2017 07:49pm EDT 

Csl Ltd - : Has become aware that Shire Viropharma has filed a complaint in us district court for district of delaware . CSL remains highly confident that csl830 does not infringe any valid claim of shire viropharma patent and will vigorously defend against claims .Complaint alleging infringement of a newly granted us patent in connection with a method of treating hereditary angioedema.  Full Article

BRIEF-CSL receives US FDA approval of privigen for CIDP indication

* Has approved CSL Behring's Privigen for treatment of adults with chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability Source text for Eikon: Further company coverage: